Redx Pharma Plc operates as a drug discovery and development company in the United Kingdom. It discovers and develops small molecule drugs for treating cancer and fibrosis. The company is developing RXC004, a porcupine inhibitor for the treatment of pancreatic, biliary, and gastric cancers, as well as melanoma; ROCK inhibitor for treating inflammatory disease related fibrosis; ROCK2, a Rho-associated protein kinase 2 inhibitor for the treatment of diabetic nephropathy, and IPF and NASH/liver fibrosis; and Porcupine (RXC006), a drug for idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), and liver fibrosis. It is also developing Pan-RAF inhibitor for colorectal cancer; and SHP2, a protein-tyrosine phosphatase for receptor tyrosine kinase signaling in cancer cells. Redx Pharma Plc was founded in 2010 and is based in Macclesfield, the United Kingdom.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+44-151-7064747
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees51
OptionableNot Optionable
Redx Pharma (LON:REDX) Frequently Asked Questions
What is Redx Pharma's stock symbol?
Redx Pharma trades on the London Stock Exchange (LON) under the ticker symbol "REDX."
How were Redx Pharma's earnings last quarter?
Redx Pharma PLC (LON:REDX) announced its quarterly earnings results on Monday, November, 19th. The company reported ($7.00) EPS for the quarter, missing analysts' consensus estimates of ($6.50) by $0.50. View Redx Pharma's Earnings History.
Has Redx Pharma been receiving favorable news coverage?
News articles about REDX stock have been trending somewhat positive this week, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Redx Pharma earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are some of Redx Pharma's key competitors?
Some companies that are related to Redx Pharma include 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), AorTech International (AOR), Arix Bioscience (ARIX), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Axovant Sciences (AXGT), Biocure Technology (CURE), Biotest (BIO) and Bioventix (BVXP).
Who are Redx Pharma's key executives?
Redx Pharma's management team includes the folowing people:
- Ms. Lisa Mary Whewell Anson, CEO & Director (Age 50)
- Mr. Dominic Nicholas Jackson, Interim CFO & Exec. Director (Age 38)
- Dr. Richard Armer, Chief Scientific Officer
- Dr. Andrew Saunders, Chief Medical Officer (Age 54)
- Andrew Booth, Sec.
How do I buy shares of Redx Pharma?
Shares of REDX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Redx Pharma's stock price today?
One share of REDX stock can currently be purchased for approximately GBX 7.50.
What is Redx Pharma's official website?
How can I contact Redx Pharma?
Redx Pharma's mailing address is Block 33, Mereside,, Alderley Park, MACCLESFIELD, SK10 4TG, United Kingdom. The company can be reached via phone at +44-151-7064747.
MarketBeat Community Rating for Redx Pharma (LON REDX)
MarketBeat's community ratings are surveys of what our community members think about Redx Pharma and other stocks. Vote "Outperform" if you believe REDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
